iRhythm/$IRTC
1D1W1MYTD1Y5YMAX
Capital at risk
About iRhythm
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
- Ticker
- $IRTC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,400
- Headquarters
- San Francisco, United States
- Website
- www.irhythmtech.com
iRhythm Metrics
BasicAdvanced
$4.1B
-
-$0.43
1.32
-
Price and volume
Market cap
$4.1B
Beta
1.32
52-week high
$212.00
52-week low
$100.85
Average daily volume
633K
Financial strength
Current ratio
3.855
Quick ratio
3.445
Long term debt to equity
381.99
Total debt to equity
391.084
Interest coverage (TTM)
0.81%
Profitability
EBITDA (TTM)
17.695
Gross margin (TTM)
71.45%
Net profit margin (TTM)
-1.69%
Operating margin (TTM)
1.30%
Effective tax rate (TTM)
-7.48%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
0.65%
Return on equity (TTM)
-9.63%
Valuation
Price to revenue (TTM)
4.84
Price to book
21.8
Price to tangible book (TTM)
21.9
Price to free cash flow (TTM)
102.488
Free cash flow yield (TTM)
0.98%
Free cash flow per share (TTM)
1.201
Growth
Revenue change (TTM)
25.58%
Earnings per share change (TTM)
-85.24%
3-year revenue growth (CAGR)
22.22%
10-year revenue growth (CAGR)
32.69%
3-year earnings per share growth (CAGR)
-49.21%
10-year earnings per share growth (CAGR)
-30.70%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Analyst projections of the future price of iRhythm stock.
Bulls say / Bears say
Second quarter 2026 revenue rose 20.1% year-over-year to $224.2 million, marking the seventh consecutive quarter of over 20% growth driven by sustained volume demand across core and new channels. (SEC)
Gross margin in Q2 2026 expanded by 160 basis points year-over-year to 72.8%, reflecting operational efficiencies, scale benefits, and improved product mix. (SEC)
Management raised full-year 2026 revenue guidance to $880 million–$890 million and adjusted EBITDA margin guidance to 13.0%–14.0%, signaling confidence in continued volume-led growth and profitability expansion. (SEC)
The VitalConnect acquisition agreement commits $237.5 million in cash and $50 million in stock, posing liquidity strain and potential equity dilution, and remains contingent on Hart-Scott-Rodino clearance with a $9 million reverse termination fee. (SEC)
iRhythm remains subject to an unresolved FDA warning letter with uncertain timing for closure, posing regulatory risk that could impact product operations or approval timelines. (EarningsCalls)
A $50 million settlement with Baxter and its subsidiaries reduces cash reserves and free cash flow, potentially limiting resources for strategic investments. (EarningsCalls)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
Upcoming events
No upcoming events
iRhythm News
AllArticlesVideos
Funds containing iRhythm
AllEURGBPUSD
Fund name | Fund size | $IRTC weighting |
|---|---|---|
iShares Ageing Population€AGED | €823M | 0.33% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.13% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.